These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 19411094)
21. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor. Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433 [TBL] [Abstract][Full Text] [Related]
22. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792 [TBL] [Abstract][Full Text] [Related]
23. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370 [TBL] [Abstract][Full Text] [Related]
24. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
25. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E; Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504 [TBL] [Abstract][Full Text] [Related]
26. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949 [TBL] [Abstract][Full Text] [Related]
27. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184 [TBL] [Abstract][Full Text] [Related]
28. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM; Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846 [TBL] [Abstract][Full Text] [Related]
29. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919 [TBL] [Abstract][Full Text] [Related]
31. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818 [TBL] [Abstract][Full Text] [Related]
32. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867 [TBL] [Abstract][Full Text] [Related]
33. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Cuisset T; Frere C; Quilici J; Morange PE; Camoin L; Bali L; Lambert M; Juhan-Vague I; Alessi MC; Bonnet JL Thromb Res; 2009 Feb; 123(4):597-603. PubMed ID: 18499233 [TBL] [Abstract][Full Text] [Related]
34. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. Chen WH; Lee PY; Ng W; Tse HF; Lau CP J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378 [TBL] [Abstract][Full Text] [Related]
35. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193 [TBL] [Abstract][Full Text] [Related]
36. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243 [TBL] [Abstract][Full Text] [Related]
37. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120 [TBL] [Abstract][Full Text] [Related]
38. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241 [TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD; Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740 [TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]